<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164942</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-GU-BLA-SPEC-001</org_study_id>
    <secondary_id>00009729</secondary_id>
    <nct_id>NCT02164942</nct_id>
  </id_info>
  <brief_title>LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer</brief_title>
  <official_title>LCI-GU-BLA-SPEC-001: Expression of the Aurora Kinase Family and Chemoresistance in Muscle-Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Earle Burgess</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm, observational study examining aurora kinases and&#xD;
      circulating tumor cells in subjects with bladder cancer being treated with standard&#xD;
      cisplatin-based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy&#xD;
      per standard of care. CTC and Aurora kinase expression patterns will be analyzed in subject&#xD;
      specimens for correlation with clinicopathologic outcome. Subjects will be on study for a&#xD;
      total of five years following cystectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility&#xD;
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of pathologic response rate and aurora kinase expression</measure>
    <time_frame>Within 6 months of subject enrollment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <description>Specimen Collection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with muscle-invasive urothelial carcinoma of the bladder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically confirmed American Joint Committee on Cancer seventh edition clinical&#xD;
             stage T2-4a N0-3 urothelial carcinoma of the bladder based on diagnostic transurethral&#xD;
             bladder biopsy or transurethral resection of bladder tumor (TURBT) confirming the&#xD;
             presence of urothelial carcinoma with muscularis propria invasion.&#xD;
&#xD;
          -  Archived tissue from prior biopsy/resection must be available for baseline AK&#xD;
             analysis.&#xD;
&#xD;
          -  Subjects must be eligible to undergo radical cystectomy and cisplatin-based&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Subjects with radiographically enlarged lymph nodes (short axis &gt;10 mm with CT scan or&#xD;
             MRI) should undergo percutaneous biopsy for staging in accordance with local&#xD;
             practices, though preferred, is not mandatory for study enrollment.&#xD;
&#xD;
          -  A baseline computed tomography (CT) scan with intravenous contrast of the chest,&#xD;
             abdomen and pelvis is required in all subjects. A radionuclide bone scan is also&#xD;
             required in subjects with skeletal pain or abnormally elevated alkaline phosphatase&#xD;
             values.&#xD;
&#xD;
          -  Age at least 18 years old.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL.&#xD;
&#xD;
          -  Subjects must have adequate liver function: AST and ALT less than 2.5x upper limit of&#xD;
             normal, alkaline phosphatase less than 2.5x upper limit of normal.&#xD;
&#xD;
          -  Subjects must have adequate bone marrow function: Platelets greater than 100,000&#xD;
             cells/mm3, Hemoglobin greater than 9.0g/dL and ANC greater than 1,500 cells/mm3.&#xD;
&#xD;
          -  Subjects must have adequate renal function with creatinine clearance of at least 60&#xD;
             mL/min.&#xD;
&#xD;
          -  Subjects must sign a written informed consent document and authorization for release&#xD;
             of their medical records for the purposes of research.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pure non-urothelial or mixed small cell histology identified within TURBT specimen.&#xD;
&#xD;
          -  Absence of documented urothelial carcinoma with muscularis propria invasion on&#xD;
             diagnostic transurethral bladder biopsy or transurethral resection of bladder tumor&#xD;
             (TURBT).&#xD;
&#xD;
          -  Distant metastatic disease, including non-regional lymphadenopathy and visceral&#xD;
             metastases, identified on pretreatment radiographic studies.&#xD;
&#xD;
          -  Creatinine clearance less than 60 mL/min.&#xD;
&#xD;
          -  CTCAE version 4 grade 2 or greater hearing loss.&#xD;
&#xD;
          -  CTCAE version 4 grade 2 or greater peripheral neuropathy.&#xD;
&#xD;
          -  NYHA class III heart failure or cardiac ejection fraction less than or equal to 50%.&#xD;
&#xD;
          -  Women of child-bearing age who are pregnant or breast feeding.&#xD;
&#xD;
          -  Uncontrolled and current illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Subjects with other active malignancies as defined as synchronous malignancy at the&#xD;
             time of bladder cancer diagnosis, excluding non-metastatic, non-melanoma skin cancer&#xD;
             are excluded.&#xD;
&#xD;
          -  Major surgery within 4 weeks of consent.&#xD;
&#xD;
          -  Subjects requiring therapeutic anticoagulation at the time of consent.&#xD;
&#xD;
          -  Currently enrolled on another clinical trial for the treatment of bladder cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Earle Burgess</investigator_full_name>
    <investigator_title>Earle Burgess</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

